From soy sauce to science: Remission Biotech joins NextShark Ventures to advance cancer research
NextShark Ventures is proud to welcome Remission Biotech as the latest addition to its portfolio of companies redefining the future of wellness and culturally rooted innovation. Remission Biotech is a nature-first biotechnology company dedicated to skin health and next-generation research into fungal-based wellness and cancer science.
Founded by Ken Koh, third-generation leader of the iconic Nanyang Sauce, Remission Biotech continues a legacy of time-honored fermentation expertise passed down since 1959. Koh's work in fermentation first gained international attention when studies revealed that Nanyang Sauce's naturally brewed soy sauce contained significant antioxidant and anti-aging properties.
Inspired by this discovery, Koh launched KITKOJI, a fermented skincare brand whose name combines 'koji' (the traditional fermentation mold) with 'Kit,' his daughter's name. Kitkoji quickly built a loyal following across Asia for its gentle, microbiome-friendly products.
Trending on NextShark:
But what began as skincare soon revealed a far greater potential.
In 2023, a customer in Australia contacted Koh with an unexpected message: after using Kitkoji's products, the melanoma spots on his skin had disappeared. Taken aback, Koh saw this as more than a coincidence — it was a call to investigate further.
Motivated by the possibility of scientific merit, he approached the National Cancer Centre Singapore (NCCS) to explore what might be happening on a cellular level. This moment would set Kitkoji and Koh on a bold new path: cancer research.
Trending on NextShark:
'Our past started in the kitchen, but the future is taking us to the frontiers of cancer research,' said Ken Koh, CEO of Remission Biotech and KITKOJI. 'At Remission Biotech, we've always believed that Mother Nature holds answers to questions we've barely begun to understand. This collaboration with NextShark Ventures gives us the platform to share our research and purpose with a broader global audience—while staying true to our roots in heritage fermentation and holistic wellness. Together, we are bridging heritage and healing.'
In May 2022, KITKOJI signed a formal research collaboration agreement with the National Cancer Centre Singapore (NCCS) to explore the use of fungal metabolites—bioactive molecules produced during fermentation—for cancer therapy development. The agreement is conducted through the Cancer Discovery Hub at NCCS.
Early lab tests showed that KITKOJI's proprietary extract, 'Extract K,' exhibited promising anti-cancer effects against 25 different cancers, including breast, lung, gastrointestinal, and blood cancers. The extract also demonstrated efficacy in xenograft models and led to the identification of novel compounds potentially responsible for tumor cell death.
Trending on NextShark:
'I never imagined soy sauce would lead me here,' said Koh. 'Whether in food or wellness, I've always believed nature knows best. This research is still in early stages, but the potential is beyond what we ever envisioned.'
The joint research focuses on the cancer mycobiome—the fungal ecosystem within and around tumors. By exploring how fungal-derived compounds influence cancer progression, the goal is to identify lead compounds that could form the basis of future treatments.
'These findings not only validate the anti-proliferative potential of Extract K but also highlight the immense opportunity within fungal metabolites as a new class of cancer therapeutics,' said Koh. 'This collaboration exemplifies Singapore's growing capabilities in biomedical innovation, combining KITKOJI's expertise in fungal fermentation with NCCS's world-class cancer research.'
Trending on NextShark:
The project, jointly funded by KITKOJI and NCCS, is scheduled to run for 12 months. If successful, it could lead to clinical trials and contribute significantly to global cancer treatment options.
'We are pleased to extend our partnership with KITKOJI and hope to bring innovative new therapies to patients with cancer,' said Asst Prof Jason Chan, Director at the Cancer Discovery Hub at NCCS. 'This extended collaboration reflects our shared vision to translate scientific discovery into tangible clinical outcomes.'
Remission Biotech was born out of this ongoing mission for cancer therapeutic discovery from mycobiota fermentation.
Trending on NextShark:
Its first product is the world's first spray-on herbal remedy formula designed for sensitive and sun-exposed skin. The product is gaining traction across Asia and globally for its gentle, non-invasive approach rooted in microbiome harmony.
'We're not here to overpromise—we're here to explore,' said Koh. 'Remission is about staying curious and grounded in what nature might still teach us.'
For NextShark Ventures, Remission Biotech reflects its core mission: supporting founder-led, culturally driven companies that bridge tradition with innovation. From soy sauce to biotech, and skincare to oncology, Remission Biotech is a rare example of authentic heritage unlocking global scientific impact.
'This partnership is deeply personal for me,' said Benny Luo, Founder and CEO of NextShark. 'I lost my grandmother to cancer in 2021, and I haven't been the same since. I've watched too many friends and loved ones confront this disease head-on. Supporting Remission Biotech isn't just a business decision—it's a commitment to exploring the kinds of healing we need more of in this world. I believe in what Ken is building, and I'm proud to stand behind a vision that bridges tradition, science, and hope.'
Download the NextShark App:
Want to keep up to date on Asian American News? Download the NextShark App today!
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
How To Set Up a ‘Recession-Proof' Retirement Fund
Everyone wants to feel secure in their retirement. So with 82% worried about the potential for a recession, per News Nation, this is the time to start thinking about how to make your retirement fund recession-proof. Read Next: Check Out: Here are five useful things to think about to recession-proof any investment funds that are going to be used when you retire. A Strong Diversification Strategy Is Essential Diversification is crucial. That's always been the case with investing. But if you're looking to de-risk your retirement portfolio, then increasing the diversity within it will further help recession-proof your funds. Diversification reduces the risk of exposure to any single asset class, region, sector or industry. For example, even if a small recession does hit America, you could invest more in European or Asian stocks, bonds, currencies and assets. Even gold, wine, art and cryptocurrencies can serve as useful diversification tactics. Make sure your portfolio includes a smart mix of equities, bonds, low-cost index funds, exchange-traded funds (ETFs) and cash equivalents to maximize your diversification and reduce exposure to any recessionary risks. Be Aware: Invest In Dividend-Paying Stocks Businesses that pay dividends can be a good investment because those dividends could mean consistent income, even in volatile markets. With dividend-paying stocks, investors get a percentage back from what they invest in the form of a dividend payment. And these dividends often come from stable, blue chip companies. When picking these stocks (as part of a balanced, risk-adjusted portfolio), look for companies with long histories of increasing dividends. Or at very least, look for companies with stable dividends and steady growth, not hypergrowth and crashes. Think about industries that aren't exciting but are always going to be around, recession or no recession. As always, remember that past performance does not indicate the likelihood of future results. Invest only what you can afford, and never invest more than you can afford to lose. That's why a diversified portfolio is crucial. Include Defensive Investment Assets Having defensive investment assets in your portfolio can help preserve your capital and maintain predictable income. Some of the most well-known defensive assets you can hold are cash and gold. Alongside cash (money in a high-interest savings account) and gold (either physical gold or via gold-based ETFs), the following are considered useful defensive investment assets to have in your portfolio: Treasury Inflation-Protected Securities (TIPS) High-quality corporate or municipal bonds U.S. federal government bonds (Treasurys) Annuities with guaranteed income (but do exercise caution). If you want to make the most of these assets, stagger bond maturities to increase income flows and the returns you generate. You can then reinvest those returns to keep growing your portfolio as part of your retirement planning. Keep a Cash Reserve and Have a Short-Term Bond Fund Having liquid cash in a high-yield savings account, or spread across several accounts, is smart. If you can, accumulate six to 24 months' worth of living expenses in these accounts, depending on your risk tolerance and how you are investing the rest of your funds. Holding on to cash is useful for a couple of other reasons too. It can help you avoid the need to sell assets during downturns, and that includes avoiding having to divest any stocks or assets in your pension fund. It also can help cover expenses during bear markets or any unexpected personal emergencies. Short-term bond funds can also be a good option. As long as you can liquidate them at a moment's notice, then you might earn a slightly higher interest rate in bonds. Avoid Overexposure to High-Risk Assets You may think that generating high returns is the way to have as much in your retirement fund as possible. But the danger of investing in assets that promise high returns is that you could be overexposed and risk losing money if those same assets suddenly crash. It's important to avoid investing too much in speculative stocks, crypto or tech-heavy funds. You'll notice how quickly overhyped stocks or crypto can suddenly collapse when the market turns against them. Also, avoid illiquid or highly leveraged assets. Whenever possible, make sure to periodically shift allocations based on age, market conditions and goals. As retirement nears, consider allocating your funds toward more income and capital preservation. More From GOBankingRates 3 Luxury SUVs That Will Have Massive Price Drops in Summer 2025 Clever Ways To Save Money That Actually Work in 2025 I'm a Retired Boomer: 6 Bills I Canceled This Year That Were a Waste of Money This article originally appeared on How To Set Up a 'Recession-Proof' Retirement Fund Sign in to access your portfolio
Yahoo
6 minutes ago
- Yahoo
Search Monetization Slips: Why Baidu's (BIDU) AI Is a Double-Edged Sword
Baidu, Inc. (NASDAQ:BIDU) is one of the AI Stocks Investors Should Keep an Eye On. On July 30, Tiger Securities maintained Buy on the stock and cut the price target to $100.00 (from $110.00). The price target cut follows the firm's downward revision of Baidu's revenue and profit estimates driven by AI-driven drags from search monetization. According to the firm, there have been challenges with monetizing AI-generated search results. These now account for an estimated 50% of total queries. 'We are maintaining our BUY rating but lowering PT to $100 (from $110) as we revise down our revenue and profit estimates to reflect the ongoing drag from AI-driven changes in search monetization. AI-generated search results now account for approximately 50% of total queries, up from 35% in April, while the monetization model remains in the testing phase. Additionally, the consolidation of YY is expected to weigh on BIDU's advertising revenue, as YY was previously one of BIDU's top advertising clients. As a result, we are lowering our 2025 ad revenue forecasts." A modern internet space with a person using Baidu services on a laptop. "Given that advertising is BIDU's primary profit driver, we are also revising down our profit estimates. Specifically, we now expect core advertising revenue to decline 18% y/y in 2Q and 3Q, with core non-GAAP operating income down 45% and 44% y/y, respectively. On a more positive note, we are maintain our forecast of +25% year-over-year growth in 2Q cloud revenue, and we are raising our estimate for other revenue to reflect the consolidation of YY'. Baidu, Inc. (NASDAQ:BIDU) is a Chinese internet giant and AI pioneer, known for its noteworthy investments in artificial intelligence technology and its position as the dominant search engine within the country. While we acknowledge the potential of BIDU as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Must-Watch AI Stocks on Wall Street and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14 minutes ago
- Yahoo
Morning bid: Dangers abound ahead of deadline day
A look at the day ahead in European and global markets from Gregor Stuart Hunter We are now about halfway through the most action-packed part of the week. The eye of the storm, if you will. In case you have forgotten, today we are catching up on corporate earnings, key economic data releases, several central bank interest rate decisions, and all the latest twists and turns in trade negotiations before new U.S. tariffs kick in on Friday. Hot off the presses: The yen appreciated 0.6% immediately after the Bank of Japan kept rates on hold as widely expected. Markets are focused on an upwards revision in inflation forecasts, with Governor Ueda due to speak shortly as traders anticipate rate hikes may be back on the agenda this year. With second-quarter earnings season halfway complete, Nasdaq futures ripped 1.3% higher after blow-out earnings from Microsoft and Meta Platforms. The U.S. dollar held steady after hitting a two-month high, on track to tally its first monthly gain all year. [FRX/] "It has been a great earnings season so far, and that's the primary reason why U.S. stocks continue to do well, but the full brunt of the tariffs hasn't been felt," said David Chao, global market strategist for Asia-Pacific at Invesco in Singapore. MSCI's broadest index of Asia-Pacific shares outside Japan fell 0.7%, though it was still on track for its fourth consecutive monthly increase. Stocks in Hong Kong led declines, down 1.1% after official PMI gauges showed weaker-than-expected activity during July. Copper futures plunged 19.4% after U.S. President Donald Trump said the U.S. will impose a 50% tariff on copper. The Korean won appreciated 0.1% after Trump said the U.S. will charge a 15% tariff on imports from South Korea. The Asian country will invest $350 billion in U.S. projects and purchase $100 billion in U.S. energy products. The announcement is the latest in a series of trade policy deals rushed out before the August 1 deadline that Trump set for trade deals before the U.S. imposes what he called Liberation Day tariffs. Trump also issued a blitz of tariff announcements ranging from goods from Brazil to small-value shipments from overseas. In early European trades, pan-region futures were up 0.2%, German DAX futures were up 0.2% and FTSE futures were up 0.1% ahead of another flurry of earnings and inflation data. Key developments that could influence markets on Thursday: * US earnings: Apple, Mastercard * European earnings: Shell, Unilever, British AmericanTobacco, London Stock Exchange Group * German data: Import prices for June, unemployment forJuly, preliminary CPI and HICP for July * French data: Preliminary CPI for July, producer prices forJune * Eurozone data: Unemployment for June Trying to keep up with the latest tariff news? Our new daily news digest offers a rundown of the top market-moving headlines impacting global trade. Sign up for Tariff Watch here. (By Gregor Stuart Hunter; Editing by Christopher Cushing) Sign in to access your portfolio
